Editas Medicine Inc

NASDAQ:EDIT  
41.50
+1.14 (+2.82%)
4:15:14 PM EDT: $41.79 +0.29 (+0.70%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.88B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$6.38 Million
Adjusted EPS-$0.76
See more estimates
10-Day MA$45.22
50-Day MA$63.85
200-Day MA$41.23
See more pivots

Editas Medicine, Inc. Stock, NASDAQ:EDIT

11 Hurley Street, 11 Hurley Street, Cambridge, Massachusetts 02142
United States of America
Phone: +1.617.401.9000
Number of Employees: 208

Description

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.